AAAAAA

   
Results: 1-21 |
Results: 21
INFLUENCE OF CD34 CELL SELECTION ON THE INCIDENCE OF MIXED CHIMERISM AND MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC UNRELATED DONOR TRANSPLANTATION
Authors: SOCIE G CAYUELA JM RAYNAL B ESPEROU H FUND X RAFFOUX C DEVERGIE A RIBAUD P MAROLLEAU JP PARQUET N SIGAUX F BRISON O GLUCKMAN E
Citation: G. Socie et al., INFLUENCE OF CD34 CELL SELECTION ON THE INCIDENCE OF MIXED CHIMERISM AND MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC UNRELATED DONOR TRANSPLANTATION, Leukemia, 12(9), 1998, pp. 1440-1446
TRANSPLANTATION FOR FANCONIS-ANEMIA (FA) - LONG-TERM FOLLOW-UP OF 50 PATIENTS (PTS) TRANSPLANTED FROM A SIBLING DONOR AFTER LOW-DOSE CYCLOPHOSPHAMIDE AND THORACOABDOMINAL IRRADIATION FOR CONDITIONING
Authors: SOCIE G DEVERGIE A GIRINSKI T PIEL G RIBAUD P ESPEROU H PARQUET N BRISON O GLUCKMAN E
Citation: G. Socie et al., TRANSPLANTATION FOR FANCONIS-ANEMIA (FA) - LONG-TERM FOLLOW-UP OF 50 PATIENTS (PTS) TRANSPLANTED FROM A SIBLING DONOR AFTER LOW-DOSE CYCLOPHOSPHAMIDE AND THORACOABDOMINAL IRRADIATION FOR CONDITIONING, Bone marrow transplantation, 21, 1998, pp. 168-168
ADVANTAGES OF GENO IDENTICAL BMT WITH A NON TOXIC CONDITIONING REGIMEN AS FIRST LINE TREATMENT FOR CHRONIC MYELOID-LEUKEMIA
Authors: DEVERGIE A PARQUET N GARDERET L ESPEROU H SOCIE G RIBAUD P GLUCKMAN E
Citation: A. Devergie et al., ADVANTAGES OF GENO IDENTICAL BMT WITH A NON TOXIC CONDITIONING REGIMEN AS FIRST LINE TREATMENT FOR CHRONIC MYELOID-LEUKEMIA, Bone marrow transplantation, 21, 1998, pp. 286-286
USE OF FILTERED BLOOD PRODUCTS FOR THE PREVENTION OF TRANSFUSION-ASSOCIATED CYTOMEGALOVIRUS (CMV) INFECTION AFTER ALLOGENEIC MARROW TRANSPLANT
Authors: TRAINEAU R SCIEUX C AGBALIKA F RIBAUD P SOCIE G ESPEROU H DEVERGIE A PARQUET N BENBUNAN M GLUCKMAN E
Citation: R. Traineau et al., USE OF FILTERED BLOOD PRODUCTS FOR THE PREVENTION OF TRANSFUSION-ASSOCIATED CYTOMEGALOVIRUS (CMV) INFECTION AFTER ALLOGENEIC MARROW TRANSPLANT, Bone marrow transplantation, 21, 1998, pp. 475-475
HODGKINS-DISEASE OF DONOR ORIGIN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MYELOGENEOUS CHRONIC LEUKEMIA
Authors: MEIGNIN V DEVERGIE A BRICE P BRISON O PARQUET N RIBAUD P COJEAN I GAULARD P GLUCKMAN E SOCIE G JANIN A
Citation: V. Meignin et al., HODGKINS-DISEASE OF DONOR ORIGIN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MYELOGENEOUS CHRONIC LEUKEMIA, Transplantation, 65(4), 1998, pp. 595-597
UNUSUAL COMPLICATIONS AFTER BONE-MARROW TRANSPLANTATION FOR DYSKERATOSIS-CONGENITA
Authors: ROCHA V DEVERGIE A SOCIE G RIBAUD P ESPEROU H PARQUET N GLUCKMAN E
Citation: V. Rocha et al., UNUSUAL COMPLICATIONS AFTER BONE-MARROW TRANSPLANTATION FOR DYSKERATOSIS-CONGENITA, British Journal of Haematology, 103(1), 1998, pp. 243-248
TRANSPLANTATION FOR FANCONI ANEMIA - LONG-TERM FOLLOW-UP OF 50 PATIENTS TRANSPLANTED FROM A SIBLING DONOR AFTER LOW-DOSE CYCLOPHOSPHAMIDE AND THORACOABDOMINAL IRRADIATION FOR CONDITIONING
Authors: SOCIE G DEVERGIE A GIRINSKI T PIEL G RIBAUD P ESPEROU H PARQUET N MAAREK O NOGUERA MH RICHARD P BRISON O GLUCKMAN E
Citation: G. Socie et al., TRANSPLANTATION FOR FANCONI ANEMIA - LONG-TERM FOLLOW-UP OF 50 PATIENTS TRANSPLANTED FROM A SIBLING DONOR AFTER LOW-DOSE CYCLOPHOSPHAMIDE AND THORACOABDOMINAL IRRADIATION FOR CONDITIONING, British Journal of Haematology, 103(1), 1998, pp. 249-255
HODGKINS-DISEASE OF DONOR ORIGIN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MYELOGENEOUS CHRONIC LEUKEMIA
Authors: MEIGNIN V DEVERGIE A BRICE P BRISON O PARQUET N RIBAUD P COJEAN I GAULARD P GLUCKMAN E SOCIE G JANIN A
Citation: V. Meignin et al., HODGKINS-DISEASE OF DONOR ORIGIN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MYELOGENEOUS CHRONIC LEUKEMIA, British Journal of Haematology, 102(1), 1998, pp. 211-211
SHORT-TERM AND LONG-TERM FOLLOW-UP OF THYROID-DYSFUNCTION AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION WITHOUT THE USE OF PREPARATIVE TOTAL-BODY IRRADIATION
Authors: TOUBERT ME SOCIE G GLUCKMAN E ARACTINGI S ESPEROU H DEVERGIE A RIBAUD P PARQUET N SCHLAGETER MH BERESSI JP RAIN JD VEXIAU P
Citation: Me. Toubert et al., SHORT-TERM AND LONG-TERM FOLLOW-UP OF THYROID-DYSFUNCTION AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION WITHOUT THE USE OF PREPARATIVE TOTAL-BODY IRRADIATION, British Journal of Haematology, 98(2), 1997, pp. 453-457
BONE-MARROW CD34-300 BAXTER) IN ALLOGENIC BONE-MARROW TRANSPLANTATIONWITH UNRELATED DONOR (UD. BMT) - PROCESSING RESULTS( SELECTION BY IMMUNOMAGNETIC METHOD (ISOLEX)
Authors: MAROLLEAU JP ESPEROU H DALCORTIVO L ROBERT I PARQUET N ZINI JM TRAINEAU R GLUCKMAN E BENBUNAN M
Citation: Jp. Marolleau et al., BONE-MARROW CD34-300 BAXTER) IN ALLOGENIC BONE-MARROW TRANSPLANTATIONWITH UNRELATED DONOR (UD. BMT) - PROCESSING RESULTS( SELECTION BY IMMUNOMAGNETIC METHOD (ISOLEX), Blood, 90(10), 1997, pp. 4337-4337
PRELIMINARY-RESULTS OF CIDOFOVIR (HPMPC) FOR THE TREATMENT OF ADENOVIRUS DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) PATIENTS
Authors: RIBAUD P SCIEUX C PARQUET N CARBONNEL E SOCIE G EMPEROU H DEVERGIE A SELIMI F GLUCKMAN E
Citation: P. Ribaud et al., PRELIMINARY-RESULTS OF CIDOFOVIR (HPMPC) FOR THE TREATMENT OF ADENOVIRUS DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) PATIENTS, Blood, 90(10), 1997, pp. 4432-4432
ENRICHED CD34-MARROW CELLS WITH ISOLEX-300 (BAXTER(TM)) DEVICES REDUCE SEVERE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH UNRELATED DONOR (UD-BMT)( BONE)
Authors: ESPEROU H MAROLLEAU JP ROCHA V DALCORTIVO L SEDKI M PARQUET N RAFFOUX C TRAINEAU R SOCIE G BENBUNAN M GLUCKMAN E
Citation: H. Esperou et al., ENRICHED CD34-MARROW CELLS WITH ISOLEX-300 (BAXTER(TM)) DEVICES REDUCE SEVERE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH UNRELATED DONOR (UD-BMT)( BONE), Blood, 90(10), 1997, pp. 483-483
VENOOCCLUSIVE DISEASE AFTER BONE-MARROW T RANSPLANTATION - USE OF HEPARIN FOR PREVENTION OF LIVER VENOOCCLUSIVE DISEASE
Authors: PARQUET N DEVERGIE A SOCIE G RIBAUD P ESPEROU H GLUCKMAN E
Citation: N. Parquet et al., VENOOCCLUSIVE DISEASE AFTER BONE-MARROW T RANSPLANTATION - USE OF HEPARIN FOR PREVENTION OF LIVER VENOOCCLUSIVE DISEASE, Annales de medecine interne, 148(2), 1997, pp. 132-135
FULMINANT ADENOVIRUS HEPATITIS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: BERTHEAU P PARQUET N FERCHAL F GLUCKMAN E BROCHERIOU C
Citation: P. Bertheau et al., FULMINANT ADENOVIRUS HEPATITIS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 17(2), 1996, pp. 295-298
AN OUTBREAK OF INVASIVE ASPERGILLOSIS AMONG BONE-MARROW TRANSPLANTS -CLINICAL-RESULTS AND EPIDEMIOLOGIC FINDINGS
Authors: PARQUET N RIBAUD P CHASTANG C LATGE JP SARFATI J BAFFROYLAFITTE L DEVERGIE A ESPEROUBOURDEAU H TRAORE F BOUAKLINE A DEKERVILER E GLUCKMAN E
Citation: N. Parquet et al., AN OUTBREAK OF INVASIVE ASPERGILLOSIS AMONG BONE-MARROW TRANSPLANTS -CLINICAL-RESULTS AND EPIDEMIOLOGIC FINDINGS, Experimental hematology, 23(8), 1995, pp. 856-856
MONITORING OF CMV INFECTION AND DISEASE AFTER BONE-MARROW TRANSPLANTATION BY CMV ANTIGEN-DETECTION IN PERIPHERAL-BLOOD LEUKOCYTES
Authors: PARQUET N LEHMAN D SCIEUX C DEVERGIE A MORINET F GLUCKMAN E
Citation: N. Parquet et al., MONITORING OF CMV INFECTION AND DISEASE AFTER BONE-MARROW TRANSPLANTATION BY CMV ANTIGEN-DETECTION IN PERIPHERAL-BLOOD LEUKOCYTES, Experimental hematology, 23(8), 1995, pp. 856-856
ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA IN 2ND REMISSION - FACTORS PREDICTIVE OF SURVIVAL, RELAPSE AND GRAFT-VERSUS-HOST DISEASE
Authors: MOUSSALEM M BOURDEAU HE DEVERGIE A BARUCHEL A RIBAUD P SOCIE G PARQUET N TRAINEAU R HIRSCH I SCHAISON G GLUCKMAN E
Citation: M. Moussalem et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA IN 2ND REMISSION - FACTORS PREDICTIVE OF SURVIVAL, RELAPSE AND GRAFT-VERSUS-HOST DISEASE, Bone marrow transplantation, 15(6), 1995, pp. 943-947
KS-ASSOCIATED HERPESVIRUS-LIKE DNA-SEQUENCES AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: GLUCKMAN E PARQUET N SCIEUX C DEPLANCHE M TRAINEAU R BETHEAU P MORINET F
Citation: E. Gluckman et al., KS-ASSOCIATED HERPESVIRUS-LIKE DNA-SEQUENCES AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Lancet, 346(8989), 1995, pp. 1558-1559
INVASIVE ASPERGILLOSIS (IA) AFTER ALLOGENEIC MARROW TRANSPLANTATION -SURVIVAL, PROGNOSTIC FACTORS AND MOLECULAR EPIDEMIOLOGY IN 27 CASES OBSERVED IN A SINGLE-CENTER
Authors: RIBAUD P CHASTANG CI LATGE JP SERFATI J BAFFROYLAFITTE L PARQUET N DEVERGIE A ESPEROU H SOCIE G TRAORE F BOUAKLINE A GLUCKMAN E
Citation: P. Ribaud et al., INVASIVE ASPERGILLOSIS (IA) AFTER ALLOGENEIC MARROW TRANSPLANTATION -SURVIVAL, PROGNOSTIC FACTORS AND MOLECULAR EPIDEMIOLOGY IN 27 CASES OBSERVED IN A SINGLE-CENTER, Blood, 86(10), 1995, pp. 843-843
PLACENTAL CORD-BLOOD BANKING AND TRANSPLANT
Authors: GLUCKMAN E TRAINEAU R BROSSARD U DALCORTIVO L DEVERGIE A RIBAUD P ESPEROU H SOCIE G PARQUET N
Citation: E. Gluckman et al., PLACENTAL CORD-BLOOD BANKING AND TRANSPLANT, Blood, 86(10), 1995, pp. 1546-1546
IDENTIFICATION OF 3 NOVEL SPECTRIN ALPHA-I 74 MUTATIONS IN HEREDITARYELLIPTOCYTOSIS - FURTHER SUPPORT FOR A TRIPLE-STRANDED FOLDING UNIT MODEL OF THE SPECTRIN HETERODIMER CONTACT SITE/
Authors: PARQUET N DEVAUX I BOULANGER L GALAND C BOIVIN P LECOMTE MC DHERMY D GARBARZ M
Citation: N. Parquet et al., IDENTIFICATION OF 3 NOVEL SPECTRIN ALPHA-I 74 MUTATIONS IN HEREDITARYELLIPTOCYTOSIS - FURTHER SUPPORT FOR A TRIPLE-STRANDED FOLDING UNIT MODEL OF THE SPECTRIN HETERODIMER CONTACT SITE/, Blood, 84(1), 1994, pp. 303-308
Risultati: 1-21 |